CYP3A4 and CYP3A5 Genotyping Recommendations

 CYP3A4 and CYP3A5 Genotyping Recommendations

This contains the webinar and continuing education credit (CME and CMLE) 


This webinar is based on new consensus recommendations from the Association for Molecular Pathology to aid in the design and validation of clinical CYP3A4 and CYP3A5 genotyping assays, promote standardization of testing across different laboratories, and improve patient care. The AMP Pharmacogenetics (PGx) Working Group with representation from Clinical Pharmacogenetics Implementation Consortium (CPIC), College of American Pathologists (CAP), Dutch Pharmacogenetics Working Group (DPWG) of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy (ESPT), Pharmacogenomics Knowledgebase (PharmGKB®), and Pharmacogene Variation Consortium (PharmVar) has developed a series of guidelines designed to help standardize clinical testing for frequently used genotyping assays. The latest report builds on the earlier recommendations for clinical genotyping of TPMT and NUDT15, CYP2C19, CYP2C9, CYP2D6, and genes important for warfarin testing and should be implemented together with other relevant clinical guidelines. The AMP PGx Working Group used the same two-tier categorization of alleles that were recommended for inclusion in the previous clinical PGx genotyping assay guidelines for the latest report.

Learning Objectives:

  • Review CYP3A4 and CYP3A5 pharmacogenetics and highlight the importance of standardization of clinical pharmacogenetics and its implications to patient care.
  • Review the AMP Pharmacogenetics (PGx) Working Group ‘Tier’ system of pharmacogenetics sequence variants/alleles recommendation.
  • Explain the key attributes of Tier 1 and Tier 2 recommended alleles for CYP3A4 and CYP3A5 genotyping.


University of Utah School of Medicine
University of Utah and ARUP Laboratories

Matthew S. Lebo, PhD, FACMG
Director of Bioinformatics at Mass General Brigham
Associate Professor of Pathology, Harvard Medical School
and Brigham and Women's Hospital

Duration: 1 Hour
Level of Instruction: Basic
Date Recorded: August 1, 2023

Planned and coordinated by the Training and Education Committee

Continuing Education Credit Information

CME credit: 1.0
CMLE credit: 1.0 
Last day to claim credit:  March 20, 2025

Accreditation Statements
AMA PRA Category 1 Credit(s)
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of American Society for Clinical Pathology (ASCP) and Association for Molecular Pathology (AMP). The American Society for Clinical Pathology (ASCP) is accredited by the ACCME to provide continuing medical education for physicians.

The ASCP designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology for 1.0 hours of CMLE credit. ASCP CMLE credit hours are acceptable for the ASCP Board of Certification (BOC) Certification Maintenance Program (CMP). CMLE credit hours meet the continuing education requirements for the ASCP Board of Certification Credential Maintenance Program (CMP) and state relicensure requirements for laboratory personnel. Participants should claim only the credit commensurate with the extent of their participation in the activity. 

Note: Members of AMP can access this webinar at no cost. Join the AMP Family!

All sales are final. No refunds will be issued.

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.